Fate Therapeutics (FATE) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $3.07 million versus the consensus estimate of $1.24 million.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Highlights Top Shopping Center REITs Ahead of Q3 Earnings
- Evercore comments on Anthropic (ANT) S-1: 'Claude Security represents the clearest n/t competitive threat to the pre-production vendors'
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
